Search

Your search keyword '"S. Cavaillon"' showing total 3 results
Start Over Author "S. Cavaillon"
3 results on '"S. Cavaillon"'

1. Bridging animal and clinical research during SARS-CoV-2 pandemic: A new-old challenge

Author

Winkler, M.S. Skirecki, T. Brunkhorst, F.M. Cajander, S. Cavaillon, J.-M. Ferrer, R. Flohé, S.B. García-Salido, A. Giamarellos-Bourboulis, E.J. Girardis, M. Kox, M. Lachmann, G. Martin-Loeches, I. Netea, M.G. Spinetti, T. Schefold, J.C. Torres, A. Uhle, F. Venet, F. Weis, S. Scherag, A. Rubio, I. Osuchowski, M.F.

Abstract

Many milestones in medical history rest on animal modeling of human diseases. The SARS-CoV-2 pandemic has evoked a tremendous investigative effort primarily centered on clinical studies. However, several animal SARS-CoV-2/COVID-19 models have been developed and pre-clinical findings aimed at supporting clinical evidence rapidly emerge. In this review, we characterize the existing animal models exposing their relevance and limitations as well as outline their utility in COVID-19 drug and vaccine development. Concurrently, we summarize the status of clinical trial research and discuss the novel tactics utilized in the largest multi-center trials aiming to accelerate generation of reliable results that may subsequently shape COVID-19 clinical treatment practices. We also highlight areas of improvement for animal studies in order to elevate their translational utility. In pandemics, to optimize the use of strained resources in a short time-frame, optimizing and strengthening the synergy between the preclinical and clinical domains is pivotal. © 2021 The Authors

Published
2021

2. 1530P Outcome of primary soft tissue or bone myoepithelial tumors (METs)

Author

Maud Toulmonde, P. Anract, Armelle Dufresne, Charles Honoré, S. Carrere, Nicolas Penel, Philippe Rosset, N. Mesli, Justine Gantzer, François Bertucci, J-B. Courreges, P. Dubray-Longeras, C. Lebbé, Yves-Marie Robin, Jennifer Wallet, S. Cavaillon, Emmanuelle Bompas, Christine Chevreau, Florence Duffaud, and C. Chemin-Airiau

Subjects
Pathology, medicine.medical_specialty, Oncology, business.industry, medicine, Myoepithelial cell, Soft tissue, Hematology, business, Outcome (game theory)
Published
2021

3. Exploring the Efficacy of Pembrolizumab in Combination with Carboplatin and Weekly Paclitaxel for Frail Patients with Advanced Non-Small-Cell Lung Cancer: A Key Investigative Study.

Author

Thomas QD, Chaabouni M, Al Herk A, Lefevbre C, Cavaillon S, Sinoquet L, Pouderoux S, Viala M, Roca L, and Quantin X

Abstract

Introduction: Immune checkpoint blockers have revolutionized the first-line treatment of advanced non-small-cell lung cancer (NSCLC). Pembrolizumab, an anti-PD-1 monoclonal antibody, is a standard therapy either alone or in combination with chemotherapy (chemo-IO). The current study explores the efficacy and safety of pembrolizumab with carboplatin and weekly paclitaxel in a cohort of frail patients., Methods: A monocentric retrospective study was conducted between 22 September 2020 and 19 January 2023 regarding patients with stage IV NSCLC treated with chemo-IO combination: carboplatin (AUC 5 mg/mL/min; Q4W), weekly paclitaxel (90 mg/m 2 on days 1, 8, and 15), and pembrolizumab (200 mg Q4W). The primary objective was real-world progression-free survival (rwPFS). Secondary objectives were overall survival (OS), toxicity profile, and outcomes based on histological subtype., Results: A total of 34 patients (20 squamous and 14 non-squamous NSCLC) benefited from the chemo-IO regimen for frail patients; 41.9% had an ECOG-PS = 2. The median age was 75.5 years. We observed an overall response rate (ORR) of 55.9%. Notably, squamous NSCLC exhibited a significantly higher ORR (80%) than non-squamous NSCLC (21.4%); p = 0.001. The median rw-PFS was 10.6 months (95% CI [6.0, NA]), with 6- and 12-month rw-PFS rates of 69% and 45.8%, respectively. The median OS was not reached, with 12- and 18-month OS rates of 75.6% and 61.4%, respectively. The median number of maintenance cycles of pembrolizumab was 5 (0; 27). Nine patients (26.5%) experienced a toxicity related to chemotherapy leading to a reduction of the dose administered and, in five patients (14.7%), to the permanent discontinuation of chemotherapy. Six patients (17.6%) had an immune-related adverse event leading to the discontinuation of immunotherapy., Discussion: Pembrolizumab plus carboplatin and weekly paclitaxel demonstrates promising efficacy and safety in frail patients with metastatic NSCLC, especially for ORR in sq-NSCLC. Prospective studies focusing on frail populations are warranted in order to validate these findings and optimize therapeutic strategies in the first-line setting.

Published
2024
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results